Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibit...

Full description

Bibliographic Details
Main Authors: Ayako Morita, Shinobu Hosokawa, Kotaro Yamada, Takahiro Umeno, Hirohisa Kano, Hiroe Kayatani, Masaaki Shiojiri, Makoto Sakugawa, Akihiro Bessho
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.13897
id doaj-673d6f4fdac44e908fb16e8e0a6039b5
record_format Article
spelling doaj-673d6f4fdac44e908fb16e8e0a6039b52021-04-14T16:29:48ZengWileyThoracic Cancer1759-77061759-77142021-04-011281248125110.1111/1759-7714.13897Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutationAyako Morita0Shinobu Hosokawa1Kotaro Yamada2Takahiro Umeno3Hirohisa Kano4Hiroe Kayatani5Masaaki Shiojiri6Makoto Sakugawa7Akihiro Bessho8Department of Allergy and Respiratory Medicine Okayama University Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanDepartment of Respiratory Medicine Japanese Red Cross Okayama Hospital Okayama JapanAbstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. Dacomitinib, another second‐generation EGFR‐tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71‐year‐old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). Afatinib was administered as the first‐line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14 months. Pemetrexed plus carboplatin followed by pemetrexed, docetaxel, atezolizumab and S‐1 were performed in sequence. Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started dacomitinib as the sixth‐line treatment. Lesions were markedly reduced and treatment with dacomitinib was continued for 7.8 months. Dacomitinib is a possible treatment option for NSCLC with uncommon mutations.https://doi.org/10.1111/1759-7714.13897afatinibdacomitinibEGFR‐TKI re‐administrationnon‐small cell lung canceruncommon EGFR mutation
collection DOAJ
language English
format Article
sources DOAJ
author Ayako Morita
Shinobu Hosokawa
Kotaro Yamada
Takahiro Umeno
Hirohisa Kano
Hiroe Kayatani
Masaaki Shiojiri
Makoto Sakugawa
Akihiro Bessho
spellingShingle Ayako Morita
Shinobu Hosokawa
Kotaro Yamada
Takahiro Umeno
Hirohisa Kano
Hiroe Kayatani
Masaaki Shiojiri
Makoto Sakugawa
Akihiro Bessho
Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
Thoracic Cancer
afatinib
dacomitinib
EGFR‐TKI re‐administration
non‐small cell lung cancer
uncommon EGFR mutation
author_facet Ayako Morita
Shinobu Hosokawa
Kotaro Yamada
Takahiro Umeno
Hirohisa Kano
Hiroe Kayatani
Masaaki Shiojiri
Makoto Sakugawa
Akihiro Bessho
author_sort Ayako Morita
title Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
title_short Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
title_full Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
title_fullStr Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
title_full_unstemmed Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
title_sort dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon egfr mutation
publisher Wiley
series Thoracic Cancer
issn 1759-7706
1759-7714
publishDate 2021-04-01
description Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibitor, has been shown to be effective in patients with uncommon mutations. Dacomitinib, another second‐generation EGFR‐tyrosine kinase inhibitor, has not previously been shown to be effective in patients with uncommon mutations. Here, we report the efficacy of dacomitinib for uncommon EGFR mutations in a 71‐year‐old woman diagnosed with metastatic lung adenocarcinoma with uncommon EGFR mutation (Ex18 G719A). Afatinib was administered as the first‐line treatment, and a remarkable antitumor effect was observed. However, the tumor grew after 14 months. Pemetrexed plus carboplatin followed by pemetrexed, docetaxel, atezolizumab and S‐1 were performed in sequence. Although approximately four years had passed since the start of treatment, her physical condition was good. The patient started dacomitinib as the sixth‐line treatment. Lesions were markedly reduced and treatment with dacomitinib was continued for 7.8 months. Dacomitinib is a possible treatment option for NSCLC with uncommon mutations.
topic afatinib
dacomitinib
EGFR‐TKI re‐administration
non‐small cell lung cancer
uncommon EGFR mutation
url https://doi.org/10.1111/1759-7714.13897
work_keys_str_mv AT ayakomorita dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT shinobuhosokawa dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT kotaroyamada dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT takahiroumeno dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT hirohisakano dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT hiroekayatani dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT masaakishiojiri dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT makotosakugawa dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
AT akihirobessho dacomitinibasaretreatmentforadvancednonsmallcelllungcancerpatientwithanuncommonegfrmutation
_version_ 1721527155102318592